About 30 % of Europe’s population is affected by water stress during an average year. The situation is expected to worsen as climate change is increasing the frequency, magnitude, and impact of droughts. A European Environment Agency (EEA) assessment, published today, presents the current state of water stress in Europe with the aim to put […]
Annual growth rate of broad monetary aggregate M3 decreased to 7.4% in September 2021 from 7.9% in August Annual growth rate of narrower monetary aggregate M1, comprising currency in circulation and overnight deposits, stood at 11.0% in September, unchanged from previous month Annual growth rate of adjusted loans to households stood at 4.1% in September, compared with 4.2% in August […]
In the week ending 22 October 2021 the net position of the Eurosystem in foreign currency (asset items 2 and 3 minus liability items 7, 8 and 9) increased by EUR 0.6 billion to EUR 320.6 billion.
The European Union (EU) achieved its three main climate and energy targets by 2020, according to a new European Environment Agency (EEA) assessment, published today. The 2030 target of a 55 % reduction in net greenhouse gas emissions can be reached if additional efforts are made and new policies are adopted and implemented.
Credit standards remained broadly unchanged for firms and tightened for housing loans Loan demand by firms and households continued to increase ECB’s monetary policy measures continue to support lending conditions and volumes
EFSA has begun work on a new assessment looking at the risk of antimicrobial resistant bacteria spreading during animal transport.
EMA’s human medicines committee (CHMP) has concluded that a booster dose of the COVID-19 vaccine Spikevax (from Moderna) may be considered in people aged 18 years and above.
ECB appoints 30 senior business professionals with proven experience Members to advise Eurosystem on design and distribution of potential digital euro Meetings of group to be held at least quarterly, starting in November 2021
EMA’s human medicines committee (CHMP) has started a rolling review of the oral antiviral medicine molnupiravir (also known as MK‑4482 or Lagevrio), developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics for the treatment of COVID‑19 in adults.
EFSA has updated its scientific guidance on the submission of food enzyme dossiers for safety evaluation.
